[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"superficial-bladder-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:superficial-bladder-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100420283","phase-1-legend-study-eg-70-in-nmibc-patients-bcg-unresponsive-and-high-risk-nmibc-incompletely-treated-with-bcg-or-bcg-nave-100420283",false,"NCT04752722","LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","A Phase 1\u002F2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment","Inclusion Criteria:\n\nBCG-unresponsive Patients:\n\n1. BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without coexisting papillary Ta\u002FT1 tumors who are ineligible for or have elected not to undergo cystectomy, and have experienced CIS disease within 12 months of treatment where: adequate BCG regimen consists of at least 2 courses of BCG where the first course (induction) must have included at least 5 or 6 doses and the second course may have included a re-induction (at least 2 treatments) or maintenance (at least 2 doses), and Cis must be documented or indicated by pathology\n\n   Phase 2 Only:\n2. BCG-Naïve or BCG-incompletely treated Patients with CIS or BCG-unresponsive, HG Ta\u002FT1 papillary disease without CIS:\n\n   -NMIBC with current Cis of the bladder, with or without coexisting papillary Ta\u002FT1 NMIBC tumor(s), who are ineligible for or have elected not to undergo cystectomy, where: either: cohort 2a) no treatment with BCG but may have previously been treated with at least 1 dose of intravesical chemotherapy following transurethral resection of bladder tumor (TURBT) and Cis must be documented or cohort 2b) indicated by pathology incomplete BCG treatment (at least 1 dose and less than the 5+2 doses required for adequate dosing per Cohort 1) or cohort 3) patients who are BCG-unresponsive following adequate treatment, with HG Ta\u002FT1 papillary disease without CIS.\n\n   All Patients:\n3. Patients who have previously been treated with a checkpoint inhibitor and failed treatment are eligible for inclusion 30 days post-treatment (Phase 1) or 3 months post-treatment (Phase 2).\n4. Male or non-pregnant, non-lactating female, 18 years or older.\n5. Women of childbearing potential must have a negative pregnancy test at Screening.\n6. Female patients of childbearing potential must be willing to consent to using highly effective birth control methods; Male patients are required to utilize a condom for the duration of the study treatment through 3 months post-dose.\n7. In Phase 2, for patients with T1 lesions may be eligible after repeat TURBT if pathology shows non-invasive (Ta or less) or no disease.\n8. Performance Status: Eastern Cooperative Oncology Group 0, 1, and 2.\n9. Hematologic inclusion: a. Absolute neutrophil count \\>1,500\u002Fmm3. b. Hemoglobin \\>9.0 g\u002FdL. c. Platelet count \\>100,000\u002Fmm3.\n10. Hepatic inclusion: a. Total bilirubin must be ≤1.5 x the upper limit of normal (ULN). b. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase ≤2.5 x ULN.\n11. Adequate renal function with creatinine clearance \\>30 mL\u002Fmin\n12. Prothrombin time and partial thromboplastin time ≤1.25 x ULN or within the therapeutic range if on anticoagulation therapy.\n13. Must have satisfactory bladder function with ability to retain study drug for 60 minutes.\n\nExclusion Criteria:\n\n1. Active malignancies (i.e., progressing or requiring treatment change in the last 24 months). Exceptions allowed under Sponsor review.\n2. Concurrent treatment with any chemotherapeutic agent.\n3. History of partial cystectomy.\n4. Treatment with last therapeutic agent (including intravesical chemotherapy post-TURBT) within 30 days of Screening (prior to the screening biopsy).\n5. Patients who have received systemic immunosuppressive medication including high-dose corticosteroids.\n6. History of severe asthma or other respiratory diseases.\n7. History of unresolved vesicoureteral reflux or an indwelling urinary stent.\n8. History of unresolved hydronephrosis due to ureteral obstruction.\n9. Participation in any other research protocol involving administration of an investigational agent within 30 Days prior to screening or any prior treatment of NMIBC with any investigational gene or immunotherapy agent.\n10. History of external beam radiation to the pelvis or prostate brachytherapy within the last 12 months.\n11. History of interstitial lung disease and\u002For pneumonitis in patients who have previously received a PD-1 or PD-L1 inhibitor therapy.\n12. Evidence of metastatic disease.\n13. History of difficult catheterization that in the opinion of the Investigator will prevent administration of EG-70.\n14. Active interstitial cystitis on cystoscopy or biopsy.\n15. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.\n16. Known human immunodeficiency virus, Hepatitis B, or Hepatitis C infection.\n17. Significant cardiovascular risk (e.g., coronary stenting within 8 weeks, myocardial infarction within 6 months).\n18. Hypersensitivity to any of the excipients of the study drug.\n\nExclusionary for Bladder Rinse cohort: known allergy to polidocanol","ALL","18 Years",{"count":19,"type":20},350,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC.\n\nThis study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with: NMIBC with CIS for whom BCG therapy is unresponsive, and other high risk patients with NMIBC.\n\nA Substudy will include a surfactant bladder rinse prior to the instillation of detalimogene in patients with NMIBC with CIS for whom BCG therapy is unresponsive.",[27,28],"Superficial Bladder Cancer","Non-muscle Invasive Bladder Cancer With Carcinoma in Situ",[30,31,32,33,34,35,36,37,38,39,40,41,42],"Non-muscle invasive bladder cancer (NMIBC)","Bacillus calmette- guerin (BCG) failure","BCG unresponsive","NMIBC","Bladder Cancer","LEGEND Study","EG-70","High-risk NMIBC","BCG-naïve","Incomplete BCG treatment","Carcinoma in situ (Cis)","BCG-exposed","Surfactant Bladder Rinse","RECRUITING","2026-06-18",{"date":46,"type":47},"2026-06-22","ACTUAL",{"date":49,"type":47},"2021-04-22",{"date":51,"type":20},"2028-11-30",{"name":53,"class":54},"enGene, Inc.","INDUSTRY",102,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":65,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100314929","phase-2-phase-ii-study-of-oral-metformin-for-intravesical-treatment-of-non-muscle-invasive-bladder-cancer-100314929","NCT03379909","Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer","TROJAN","Inclusion Criteria:\n\n* Age \\> 18 years.\n* Patients with primary or recurrent suspectedTa or T1, G1 or G2 (low grade) urothelial carcinoma of the bladder with no suspicion of carcinoma in situ.\n* Patients must have at least 1 lesion but no more than 5.\n* There must be one index lesion measuring between 0.5 and 1.0 cm in its greatest dimension.\n* Bimanual examination immediately following cystoscopyshould be carried out and no mass should be felt.\n* Adequate renal function (eGFR \\>50 ml\u002Fmin\u002F1.73m2 according to CKD-EPI). (47)\n* Adequate liver function (bilirubin \\\u003C1.5 times upper limit of normal, ALAT or ASAT \\\u003C2.5 the upper limit of normal).\n* Eligible patients must be fully informed of the investigational nature of the study and written signed informed consent must be obtained prior to any study specific investigations.\n* Mentally, physically, and geographically able to undergo treatment and follow up.\n\nExclusion Criteria:\n\n* Patients with positive cytology (suspected for high-grade urothelial carcinoma, TPS 4 or TPS 5) or suspected grade 3 tumours.\n* Patients with diabetes mellitus receiving metformin or having received metformin in the past 6 months.\n* Patients who have received intravesical treatment (chemotherapy or immunotherapy) within the last 3 months.\n* Patients that are currently receiving other anti-cancer therapy.\n* Patients with existing urinary tract infection or recurrent severe bacterial cystitis.\n* Patients that need to be treated with a transurethral catheter.\n* Patients with urogenital tumours with histology other than urothelial carcinoma (i.e. squamous cell or adenocarcinoma) or with urothelial carcinoma involving the upper tract or the prostatic urethra.\n* Patients with a history of other primary malignancy (other than squamous or basal cell skin cancers or cone biopsied CIS of the uterine cervix or prostate carcinoma treated curatively with normal PSA values at inclusion) in the last five years.\n* Patients with active, uncontrolled impairment of the renal, hepatobiliary, cardiovascular, gastrointestinal, urogenital, neurologic or hematopoietic systems that, in the opinion of the investigator, would predispose to the development of complications from the administration of metformin.\n* Patients who are using loop diuretics, cimetidine, ranitidine, cetirizine, trimethoprim, vandetanib, kinidine and\u002For HIV medication, for which no reasonable alternative is available.\n* Women who are pregnant or lactating. Individuals of reproductive potential may not participate unless agreeing to use an effective contraceptive method for themselves and\u002For their sexual partner.\n* Patients with ECOG-WHO performance status of 3 or 4.\n* Patients with a known history of alcohol abuse.\n* Patients with a known hypersensitivity to metformin.\n* Patients who in the investigator's opinion, cannot comply with provisions of the protocol or do not understand the nature of the study.",{"count":64,"type":20},49,[24],"A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.",[27,34],[69,70],"metformin","marker lesion","2023-09-19",{"date":73,"type":47},"2023-09-21",{"date":75,"type":47},"2019-09-01",{"date":77,"type":20},"2029-10-01",{"name":79,"class":80},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",3]